Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NLRP3 | Q96P20 | 11/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 3/20 | 0.37 |
| ▸ | FPR1 | P21462 | 1/20 | 0.34 |
| ▸ | FPR3 | P25089 | 1/20 | 0.34 |
| ▸ | FPR2 | P25090 | 1/20 | 0.34 |
| ▸ | SAE1 | Q9UBE0 | 1/20 | 0.34 |
| ▸ | UBA2 | Q9UBT2 | 1/20 | 0.34 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23950422 | 0.81 | LMNA (0.38) | NLRP3 | |
| SCHEMBL23950522 | 0.77 | KDM4E (0.42) | — | |
| SCHEMBL23950430 | 0.76 | NLRP3 (0.61) | NLRP3TP53KCNH2 | |
| SCHEMBL23950434 | 0.75 | NLRP3 (0.65) | NLRP3TP53FPR1FPR3FPR2 | |
| SCHEMBL23950174 | 0.73 | NLRP3 (0.42) | NLRP3KCNH2 | |
| SCHEMBL23898870 | 0.73 | NLRP3 (0.63) | NLRP3KCNH2 | |
| SCHEMBL23950167 | 0.72 | NLRP3 (0.42) | NLRP3TP53FPR1FPR3FPR2 | |
| SCHEMBL23950423 | 0.71 | NLRP3 (0.72) | NLRP3FPR1FPR3FPR2 | |
| SCHEMBL25819173 | 0.70 | NLRP3 (0.54) | NLRP3MAPTTP53 | |
| SCHEMBL23950364 | 0.70 | KDM4E (0.43) | NLRP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230203044-A1 | PYRAZOLO[1,5-D][1,2,4]TRIAZINE-5(4H)-ACETAMIDES AS INHIBITORS OF THE NLRP3 INFLAMMASOME | JANSSEN PHARMACEUTICA NV (BE) | 2023-06-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230203044-A1 | PYRAZOLO[1,5-D][1,2,4]TRIAZINE-5(4H)-ACETAMIDES AS INHIBITORS OF THE NLRP3 INFLAMMASOME | NLRP3, PYCARD, NLRP1 | NLRP3 1/4885MAPT 1369/4885TP53 2445/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.